MEDIAN TECHNOLOGIES (EPA:ALMDT) | WebDisclosure

Basculer en Français

10443	Companies
219223	Keywords
148681	Articles
115959	Press releases

Home
Companies
MEDIAN TECHNOLOGIES

PRESS RELEASE

published on 02/09/2026 at 07:00, 3 months 13 days ago

Inside Information / Operations of the issuer (acquisitions, sales...)
Median Technologies receives FDA 510(k) clearance for eyonis® LCS, the first AI tech-based detection and diagnosis device for lung cancer screening. The device aims to redefine lung cancer screening with high accuracy and potential to save lives

FDA Clearance AI Technology Median Technologies Eyonis LCS Lung Cancer Screening
PRESS RELEASE

published on 02/09/2026 at 07:00, 3 months 13 days ago

Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Median Technologies obtient l'autorisation 510(k) de la FDA pour eyonis® LCS, logiciel IA dépistage cancer poumon. Nouveau paradigme dépistage. Déploiement à grande échelle en cours

Dépistage Median Technologies Cancer Du Poumon Autorisation 510(k) Eyonis® LCS
BRIEF

published on 01/14/2026 at 17:50, 4 months 8 days ago

Median Technologies : Calendrier Financier et Participation à des Conférences en 2026

Calendrier Financier Résultats Annuels Conférences Investisseurs Median Technologies Imagerie Médicale IA
BRIEF

published on 01/14/2026 at 17:50, 4 months 8 days ago

Median Technologies: Financial Calendar and Conference Participation in 2026

Investor Conferences Financial Calendar Annual Results Median Technologies AI-powered Medical Imaging
PRESS RELEASE

published on 01/14/2026 at 17:45, 4 months 8 days ago

Informations privilégiées / Autres communiqués
Median Technologies communique son calendrier de communication financière du premier semestre 2026, incluant les résultats annuels 2025 et la participation à des conférences investisseurs

Communication Financière Intelligence Artificielle Conférences Investisseurs Calendrier Median Technologies
BRIEF

published on 12/03/2025 at 17:50, 5 months 19 days ago

Median Technologies révèle la structure des droits de vote et du capital social

Capital Social Droit De Vote Conformité Réglementaire Transparence Financière Technologies Médianes
BRIEF

published on 12/03/2025 at 17:50, 5 months 19 days ago

Median Technologies Reveals Voting Rights and Share Capital Structure

Share Capital Voting Rights Regulatory Compliance Financial Transparency Median Technologies
PRESS RELEASE

published on 12/03/2025 at 17:45, 5 months 19 days ago

Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Median Technologies discloses total voting rights & shares as of Nov 30, 2025, in compliance with French regulations. Company pioneers AI for cancer diagnosis & treatment

Voting Rights Shares French Regulations Median Technologies Cancer Diagnosis
BRIEF

published on 10/21/2025 at 17:50, 7 months 1 day ago

Median Technologies receives €19 million in financing from the EIB

Funding European Investment Bank Median Technologies Cancer Diagnosis Eyonis® LCS
BRIEF

published on 10/21/2025 at 17:50, 7 months 1 day ago

Median Technologies reçoit un financement de 19 millions d'euros de la BEI

Financement Banque Européenne D’Investissement Median Technologies Diagnostic Du Cancer Eyonis® LCS

Accesswire

Published on 05/23/2026 at 00:15, 25 minutes ago

Molten Metals Completes Airborne Geophysical Survey at Texas Project
Published on 05/23/2026 at 00:00, 40 minutes ago

Redwood AI Announces Collaboration with Resilience Biosciences Inc. to Advance AI-Assisted Small-Molecule Drug Development
Published on 05/22/2026 at 23:01, 1 hour 39 minutes ago

Water Ways Announces Corporate Updates
Published on 05/22/2026 at 18:40, 6 hours ago

Vertical Announces Grant of Options
Published on 05/22/2026 at 14:04, 10 hours 36 minutes ago

Wi2Wi Corporation Announces First Quarter 2026 Financial Results (Unaudited)

View all ACCESSWIRE

EQS Group

Published on 05/22/2026 at 22:05, 2 hours 35 minutes ago

Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 2 hours 35 minutes ago

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 4 hours 48 minutes ago

Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 18:33, 6 hours 7 minutes ago

Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring
Published on 05/22/2026 at 18:30, 6 hours 9 minutes ago

Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors

Les Echos

Published on 05/22/2026 at 19:35, 5 hours 5 minutes ago

PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 6 hours 34 minutes ago

Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 6 hours 34 minutes ago

Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 11 hours 47 minutes ago

Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 11 hours 47 minutes ago

Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026

View all LES ECHOS COMFI WIRE